SG/CALL/VERTEX PHARMACEUTICALS/350/0.1/21.06.24 | Market Closed - Deutsche Boerse AG 17:16:28 13/06/2024 BST | ||
| 11.99 EUR | +3.72% |
|
| Current month | +22.35% | ||
| 1 month | +59.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 13/06/24 | 11.99 | +3.72% |
| 12/06/24 | 11.56 | -5.79% |
| 11/06/24 | 12.27 | -1.84% |
| 10/06/24 | 12.5 | +0.32% |
| 07/06/24 | 12.46 | +0.48% |
Delayed Quote Deutsche Boerse AG
Last update June 13, 2024 at 05:16 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SQ4HDP |
| ISIN | DE000SQ4HDP8 |
| Date issued | 16/11/2022 |
| Strike | 350 $ |
| Maturity | 21/06/2024 (6 Days) |
| Parity | 10 : 1 |
| Emission price | 4.94 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.56 € |
|---|---|
| Lowest since issue | 2.44 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Warrants
- Warrant